NasdaqGS:ERASBiotechs
Erasca Confronts Trial Fatality And Lawsuit As Valuation Debate Deepens
Erasca (NasdaqGS:ERAS) disclosed a patient death in its Phase 1 ERAS-0015 trial, triggering heightened safety and regulatory scrutiny.
Revolution Medicines filed a patent infringement lawsuit against Erasca, also challenging the way ERAS-0015 has been compared to its own programs.
These events follow a recent preliminary positive data update for ERAS-0015 and introduce fresh uncertainty around the asset and broader pipeline.
Erasca comes into this twin shock with a share price of $10.03 and...